We congratulate Gilead Sciences Inc. on achieving this remarkable milestone with the ground–breaking interim results from the PURPOSE 1 HIV Prevention Trial that is currently being conducted in Uganda and South Africa. The demonstration of 100% efficacy for Lenacapavir in preventing new HIV infections among cisgender women and adolescent girls aged 16-25 from an interim analysis marks a pivotal moment in our collective fight against HIV infections.

In all actions moving forward, we insist that Gilead act with a lens that centres women and girls, who continue to bear a disproportionate burden of new HIV infections. The company’s approach must reflect the urgency of their needs.

As speed is of the essence, we call on Gilead to act quickly in translating these trial results into real-world access whilst ensuring a pragmatic approach to ensuring manufacturing quality control. However, this urgency must not come at the expense of thorough safety monitoring and community engagement... Read More